Cognition and depression: the effects of fluvoxamine, a sigma‐1 receptor agonist, reconsidered

@article{Hindmarch2010CognitionAD,
  title={Cognition and depression: the effects of fluvoxamine, a sigma‐1 receptor agonist, reconsidered},
  author={I. Hindmarch and K. Hashimoto},
  journal={Human Psychopharmacology: Clinical and Experimental},
  year={2010},
  volume={25}
}
Cognitive impairment is a primary feature of patients with major depressive disorder (MDD) and is characterised by stress‐induced neural atrophy. Via alpha‐adrenergic, anti‐cholinergic and anti‐histaminic activities, several antidepressants can cause significant counter‐therapeutic cognitive impairment. Evidence is emerging of the involvement of sigma‐1 receptor agonism in the mechanism of action of some antidepressants, notably fluvoxamine. Sigma‐1 receptors are abundant in areas affected by… Expand
The role of glutamate on the action of antidepressants
  • K. Hashimoto
  • Medicine
  • Progress in Neuro-Psychopharmacology and Biological Psychiatry
  • 2011
TLDR
The author reviews the role of glutamate in the neuron-glia communication induced by potential antidepressants and indicates that the agents which act at glutamate receptors such as NMDA receptors, α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors and metabotropic glutamate receptors (mGluRs) might have antidepressant-like activities in animal models of depression. Expand
Psychopharmacology of combined activation of the serotonin1A and &sgr;1 receptors
TLDR
The findings suggest that the functional interaction between the 5‐HT1A and &sgr;1 receptors activates prefrontal dopaminergic system under the conditions of decreased brain GABAA receptor function and the neurochemical effect is linked to the behavioral effect. Expand
Sigma-1 Receptor Agonists and Their Clinical Implications in Neuropsychiatric Disorders.
TLDR
The role of s Sigma-1 receptors in the mechanistic action of some SSRIs, donepezil, neurosteroids, and ifenprodil, and the clinical implications for sigma-1 receptor agonists are discussed. Expand
The opposite effects of fluvoxamine and sertraline in the treatment of psychotic major depression: a case report
TLDR
Doctors should consider the monotherapy of sigma-1 receptor agonist fluvoxamine as an alternative approach to treating psychotic major depression. Expand
Neuropharmacologic studies on the brain serotonin1A receptor using the selective agonist osemozotan.
  • T. Matsuda
  • Medicine
  • Biological & pharmaceutical bulletin
  • 2013
TLDR
It is shown that osemozotan attenuates psychostimulant-induced behavioral sensitization and that prefrontal dopamine release is enhanced by functional interaction between the 5-HT1A receptor and other receptors, and suggests that the5-HT 1A receptor may be a target molecule for the treatment of psychiatric disorders, pain, and drug dependence. Expand
Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders
TLDR
Substances regulating activation/inhibition of the NMDA receptor have been investigated in schizophrenia and major depression and are promising in therapeutic approaches of negative symptoms, cognition, and mood and should be investigated to elucidate neural mechanisms underlying efficacy. Expand
Dextromethorphan as a potential rapid-acting antidepressant.
TLDR
It is hypothesized that dextromethorphan may have antidepressant efficacy in bipolar, unipolar, major depression, psychotic, and treatment-resistant depressive disorders, and may display rapid-onset of antidepressant response. Expand
Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review
Depression is the most prevalent psychiatric disorder in the world, affecting 4.4% of the global population. Despite an array of treatment modalities, depressive disorders remain difficult to manageExpand
An Emerging Role for Sigma-1 Receptors in the Treatment of Developmental and Epileptic Encephalopathies
Developmental and epileptic encephalopathies (DEEs) are complex conditions characterized primarily by seizures associated with neurodevelopmental and motor deficits. Recent evidence supports sigma-1Expand
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
TLDR
This work aims to be a reference for psychiatrists who may soon be faced with the possibility of prescribing psychedelic compounds as medications, helping them assess which compound(s) and regimen could be most useful for decreasing specific psychiatric symptoms. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 76 REFERENCES
Sigma‐1 receptor as regulator of neuronal intracellular Ca2+: clinical and therapeutic relevance
  • F. Monnet
  • Biology, Medicine
  • Biology of the cell
  • 2005
TLDR
Recent data is presented supporting the notion that drugs acting via the endoplasmic reticulum‐coupled sigma‐1 receptor might reverse these deleterious events by restoring both extra‐ and intra‐cellular Ca2+‐dependent neuronal responses. Expand
Antidepressant Treatment of Psychotic Major Depression: Potential Role of the σ Receptor
TLDR
It is proposed that the apparent efficacy of fluvoxamine in psychotic major depression may be related to its unique property of high affinity for the σ1receptor, which is thought to play a role in psychosis and in the action of some antipsychotic drugs. Expand
The interaction between neuroactive steroids and the σ1 receptor function: behavioral consequences and therapeutic opportunities
TLDR
The therapeutical interest of selective sigma1 receptor agonists in alleviating aging-related cognitive deficits will be discussed. Expand
The role of the hippocampus in the pathophysiology of major depression.
TLDR
Data from imaging studies suggest both structural changes in the volume of the HC and functional alterations in frontotemporal and limbic circuits that may be critical for mood regulation in patients with MDD. Expand
Neuroprotective and anti-amnesic potentials of sigma (σ) receptor ligands
Abstract 1. 1. Although the physical nature of sigma (σ) receptors have not yet been fully defined, several classes of selective ligands have been characterised, demonstrating a plethora ofExpand
Amitriptyline, clovoxamine and cognitive function: a placebo-controlled comparison in depressed outpatients
TLDR
Evidence is added that antidepressant drugs with high anticholinergic activity can impair memory, despite alleviation of depression, by testing the alternative hypothesis that amitriptyline would exacerbate depressed patients' cognitive disturbances. Expand
Non-serotonergic pharmacological profiles and associated cognitive effects of serotonin reuptake inhibitors
TLDR
The impairing and facilitating cognitive effects of paroxetine and sertraline, respectively, may be more pronounced in the elderly depressed patient and can be explained by subtle differences in pharmacological profiles of these SSRIs. Expand
Neurocognitive impairment in drug-free patients with major depressive disorder
TLDR
Pronounced neurocognitive impairment was found in this sample of young adult out-patients with MDD, and could therefore provide an objective marker of brain dysfunction in depression. Expand
Strain differences in σ1 receptor‐mediated behaviours are related to neurosteroid levels
The sigma1 (σ1) receptor exerts a potent neuromodulatory role in the brain with relevant consequences in memory processes, response to stress, depression and pharmacodependence. Its preciseExpand
Sigma-1 receptors and selective serotonin reuptake inhibitors: clinical implications of their relationship.
  • K. Hashimoto
  • Psychology, Medicine
  • Central nervous system agents in medicinal chemistry
  • 2009
TLDR
The novel role of sigma-1 receptors in the active mechanisms of some SSRIs including fluvoxamine including phencyclidine-induced cognitive deficits in mice are discussed. Expand
...
1
2
3
4
5
...